Other Events ·
Protalix BioTherapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 25, 2026
PLXProtalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 25, 2026. Shareholders elected eight directors and ratified Kesselman & Kesselman as the independent registered public accounting firm for the 2026 fiscal year. Additionally, stockholders approved an amended and restated 2006 Stock Incentive Plan, which increases the number of common stock shares available under the plan from 17,475,171 to 20,975,171. The meeting also included a non-binding advisory vote on executive compensation. Protalix BioTherapeutics is a biotechnology company.